NTLA · Insider Trading
Intellia Therapeutics, Inc
Every open-market purchase and sale reported by NTLA officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-06 | Michael P Dube | VP, Chief Accounting Officer | Sell | −1,864 | −$23.17K |
| 2026-08-24 | John M Leonard | President and CEO | Sell | −22,675 | −$286.82K |
| 2026-07-24 | Edward J Dulac III | EVP, Chief Financial Officer | Sell | −8,111 | −$91.25K |
| 2026-07-06 | Edward J Dulac III | EVP, Chief Financial Officer | Sell | −4,677 | −$84.19K |
| 2026-07-06 | Michael P Dube | VP, Chief Accounting Officer | Sell | −2,641 | −$44.32K |
| 2026-06-10 | Fred E Cohen | Director | A | +9,200 | — |
| 2026-06-10 | Muna Bhanji | Director | A | +9,200 | — |
| 2026-06-10 | Brian Goff | Director | A | +9,200 | — |
| 2026-06-10 | Frank Verwiel | Director | A | +9,200 | — |
| 2026-06-10 | William J Chase | Director | A | +9,200 | — |
| 2026-06-10 | Jesse Goodman | Director | A | +9,200 | — |
| 2026-06-10 | Georgia Keresty | Director | A | +9,200 | — |
| 2026-03-03 | James Basta | EVP, General Counsel | MIXED | +44,869 | −$16.69K |
| 2026-03-03 | Eliana Clark | EVP, Chief Technical Officer | MIXED | +6,746 | −$8.36K |
| 2026-03-03 | Birgit C Schultes | EVP, Chief Scientific Officer | A | +39,200 | — |
| 2026-03-03 | Edward J Dulac III | EVP, Chief Financial Officer | A | +61,280 | — |
| 2026-03-03 | David Lebwohl | EVP, Chief Medical Officer | A | +9,943 | — |
| 2026-03-03 | John M Leonard | President and CEO | A | +156,400 | — |
| 2026-03-03 | Michael P Dube | VP, Chief Accounting Officer | A | +17,250 | — |
| 2026-01-07 | Birgit C Schultes | EVP, Chief Scientific Officer | Sell | −8,508 | −$78.36K |
| 2026-01-07 | Fred E Cohen | Director | Buy | +150,000 | +$1.40M |
| 2026-01-07 | Michael P Dube | VP, Chief Accounting Officer | Sell | −2,989 | −$27.53K |
| 2026-01-07 | Edward J Dulac III | EVP, Chief Financial Officer | Sell | −6,379 | −$58.75K |
| 2026-01-07 | Eliana Clark | EVP, Chief Technical Officer | Sell | −9,515 | −$87.63K |
| 2026-01-07 | David Lebwohl | EVP, Chief Medical Officer | Sell | −11,903 | −$109.63K |
| 2026-01-07 | James Basta | EVP, General Counsel | Sell | −10,397 | −$95.76K |
| 2026-01-07 | John M Leonard | President and CEO | Sell | −34,146 | −$314.48K |
| 2025-12-12 | John M Leonard | President and CEO | MIXED | −29,630 | −$436.72K |
| 2025-10-03 | Michael P Dube | VP, Chief Accounting Officer | Sell | −1,871 | −$32.52K |
| 2025-10-03 | Birgit C Schultes | EVP, Chief Scientific Officer | Sell | −31 | −$539 |
| 2025-08-22 | William J Chase | Director | Buy | +100,000 | +$1.00M |
| 2025-07-25 | Edward J Dulac III | EVP, Chief Financial Officer | Sell | −7,462 | −$104.62K |
| 2025-07-03 | Michael P Dube | VP, Chief Accounting Officer | Sell | −2,503 | −$24.90K |
| 2025-07-03 | Eliana Clark | EVP, Chief Technical Officer | Sell | −1,022 | −$10.04K |
| 2025-07-02 | Jesse Goodman | Director | Sell | −3,094 | −$29.07K |
| 2025-06-18 | Georgia Keresty | Director | A | +8,000 | — |
| 2025-06-13 | Jesse Goodman | Director | A | +8,000 | — |
| 2025-06-13 | Muna Bhanji | Director | A | +8,000 | — |
| 2025-06-13 | William J Chase | Director | A | +8,000 | — |
| 2025-06-13 | Brian Goff | Director | A | +8,000 | — |
| 2025-06-13 | Frank Verwiel | Director | A | +8,000 | — |
| 2025-06-13 | Fred E Cohen | Director | A | +8,000 | — |
| 2025-05-01 | Muna Bhanji | Director | Sell | −265 | −$2.25K |
| 2025-03-04 | Michael P Dube | VP, Chief Accounting Officer | A | +14,000 | — |
| 2025-03-04 | Birgit C Schultes | EVP, Chief Scientific Officer | A | +37,600 | — |
| 2025-03-04 | John M Leonard | President and CEO | A | +136,000 | — |
| 2025-03-04 | Edward J Dulac III | EVP, Chief Financial Officer | A | +47,200 | — |
| 2025-03-04 | Eliana Clark | EVP, Chief Technical Officer | MIXED | +31,321 | −$6.10K |
| 2025-03-04 | David Lebwohl | EVP, Chief Medical Officer | A | +43,200 | — |
| 2025-03-04 | James Basta | EVP, General Counsel | MIXED | +37,428 | −$23.12K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| John M Leonard | President and CEO | 1,208,264 | $14.08M |
| Fred E Cohen | Director | 216,653 | $2.52M |
| James Basta | EVP, General Counsel | 158,005 | $1.84M |
| Edward J Dulac III | EVP, Chief Financial Officer | 148,175 | $1.73M |
| William J Chase | Director | 143,893 | $1.68M |
| Birgit C Schultes | EVP, Chief Scientific Officer | 137,733 | $1.60M |
| David Lebwohl | EVP, Chief Medical Officer | 131,192 | $1.53M |
| Eliana Clark | EVP, Chief Technical Officer | 93,864 | $1.09M |
| Laura Sepp-Lorenzino | EVP, Chief Scientific Officer | 77,388 | $901.57K |
| Michael P Dube | VP, Chief Accounting Officer | 65,022 | $757.51K |
| Derek Hicks | EVP, Chief Business Officer | 59,878 | $697.58K |
| Georgia Keresty | Director | 41,083 | $478.62K |
| Muna Bhanji | Director | 36,403 | $424.09K |
| Frank Verwiel | Director | 35,148 | $409.47K |
| Jesse Goodman | Director | 33,559 | $390.96K |
| Brian Goff | Director | 32,609 | $379.89K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the NTLA quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.